Literature DB >> 27383758

Assessment and management of cirrhosis in people older than 16 years: summary of NICE guidance.

P Harrison1, B J Hogan2, L Floros3, E Davies4.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27383758     DOI： 10.1136/bmj.i2850

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  Palliative long-term abdominal drains for the management of refractory ascites due to cirrhosis: a consensus document.

Authors:  Lucia Macken; Margaret Corrigan; Wendy Prentice; Fiona Finlay; Joanne McDonagh; Neil Rajoriya; Claire Salmon; Mhairi Donnelly; Catherine Evans; Bhaskar Ganai; Joan Bedlington; Shani Steer; Mark Wright; Ben Hudson; Sumita Verma
Journal:  Frontline Gastroenterol       Date:  2022-06-10

2.  Prevalence of abnormal liver tests and liver fibrosis among rural adults in low and middle-income country: A cross-sectional study.

Authors:  Arulraj Ramakrishnan; Ganesan Velmurugan; Aravindh Somasundaram; Sundaresan Mohanraj; Dinakaran Vasudevan; Paari Vijayaragavan; Peter Nightingale; Krishnan Swaminathan; James Neuberger
Journal:  EClinicalMedicine       Date:  2022-07-14

3.  Uncovering unsuspected advanced liver fibrosis in patients referred to alcohol nurse specialists using the ELF test.

Authors:  Freya Rhodes; Sara Cococcia; Jasmina Panovska-Griffiths; Sudeep Tanwar; Rachel H Westbrook; Alison Rodger; William M Rosenberg
Journal:  BMC Gastroenterol       Date:  2021-03-31       Impact factor: 3.067

4.  Guidelines on the management of ascites in cirrhosis.

Authors:  Guruprasad P Aithal; Naaventhan Palaniyappan; Louise China; Suvi Härmälä; Lucia Macken; Jennifer M Ryan; Emilie A Wilkes; Kevin Moore; Joanna A Leithead; Peter C Hayes; Alastair J O'Brien; Sumita Verma
Journal:  Gut       Date:  2020-10-16       Impact factor: 23.059

5.  NRF2 Activation Inhibits Both TGF-β1- and IL-13-Mediated Periostin Expression in Fibroblasts: Benefit of Cinnamaldehyde for Antifibrotic Treatment.

Authors:  Yasutaka Mitamura; Mika Murai; Chikage Mitoma; Masutaka Furue
Journal:  Oxid Med Cell Longev       Date:  2018-08-07       Impact factor: 6.543
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.